Stocks and Investing Stocks and Investing
Thu, May 9, 2024

Balaji Prasad Maintained (TEVA) at Buy with Increased Target to $20 on, May 9th, 2024


Published on 2024-10-28 11:09:30 - WOPRAI, Balaji Prasad
  Print publication without navigation


Balaji Prasad of Barclays, Maintained "Teva Pharmaceutical Industries Limited" (TEVA) at Buy with Increased Target from $17 to $20 on, May 9th, 2024.

Balaji has made no other calls on TEVA in the last 4 months.



There are 4 other peers that have a rating on TEVA. Out of the 4 peers that are also analyzing TEVA, 2 agree with Balaji's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Chris Schott of "JP Morgan" Upgraded from Sell to Hold and Held Target at $14 on, Friday, March 8th, 2024
  • Nathan Rich of "Goldman Sachs" Maintained at Hold with Increased Target to $11 on, Monday, February 5th, 2024


These are the ratings of the 2 analyists that currently disagree with Balaji


  • David Amsellem of "Piper Sandler" Upgraded from Hold to Buy and Increased Target to $19 on, Monday, February 12th, 2024
  • Glen Santangelo of "Jefferies" Upgraded from Hold to Strong Buy and Increased Target to $14 on, Tuesday, January 23rd, 2024
Contributing Sources